UBM Stock Overview
Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Ulisse Biomed S.p.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.45 |
52 Week High | €2.52 |
52 Week Low | €1.36 |
Beta | 0.59 |
1 Month Change | -6.75% |
3 Month Change | -15.20% |
1 Year Change | -37.23% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -54.98% |
Recent News & Updates
A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)
Jun 24We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business Growth
Feb 17Shareholder Returns
UBM | IT Biotechs | IT Market | |
---|---|---|---|
7D | -0.7% | 4.3% | 1.3% |
1Y | -37.2% | -2.7% | 25.2% |
Return vs Industry: UBM underperformed the Italian Biotechs industry which returned -1.1% over the past year.
Return vs Market: UBM underperformed the Italian Market which returned 26.4% over the past year.
Price Volatility
UBM volatility | |
---|---|
UBM Average Weekly Movement | 5.5% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 4.2% |
10% most volatile stocks in IT Market | 7.8% |
10% least volatile stocks in IT Market | 2.6% |
Stable Share Price: UBM's share price has been volatile over the past 3 months.
Volatility Over Time: UBM's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 9 | Matteo Petti | https://www.ulissebiomed.com |
Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV.
Ulisse Biomed S.p.A. Fundamentals Summary
UBM fundamental statistics | |
---|---|
Market cap | €31.28m |
Earnings (TTM) | -€1.68m |
Revenue (TTM) | €90.91k |
344.0x
P/S Ratio-18.7x
P/E RatioIs UBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
UBM income statement (TTM) | |
---|---|
Revenue | €90.91k |
Cost of Revenue | €1.06m |
Gross Profit | -€967.89k |
Other Expenses | €707.82k |
Earnings | -€1.68m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.078 |
Gross Margin | -1,064.71% |
Net Profit Margin | -1,843.32% |
Debt/Equity Ratio | 0.2% |
How did UBM perform over the long term?
See historical performance and comparison